BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 34122056)

  • 21. Effectiveness and Safety of Under or Over-dosing of Direct Oral Anticoagulants in Atrial Fibrillation: A Systematic Review and Meta-analysis of 148909 Patients From 10 Real-World Studies.
    Shen NN; Zhang C; Wang N; Wang JL; Gu ZC; Han H
    Front Pharmacol; 2021; 12():645479. PubMed ID: 33815125
    [No Abstract]   [Full Text] [Related]  

  • 22. Inappropriate dosing of direct oral anticoagulants: findings from a clinical vignette study and physician survey.
    Fuat A; Ako E; Hargroves D; Holden D; Caleyachetty A; Carter M; Harris J; Roberts C; Nzeakor N; Vardar B; Williams H
    J Mark Access Health Policy; 2023; 11(1):2267327. PubMed ID: 37954532
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral Anticoagulant Use in Elderly Japanese Patients With Non-Valvular Atrial Fibrillation - Subanalysis of the ANAFIE Registry.
    Akao M; Shimizu W; Atarashi H; Ikeda T; Inoue H; Okumura K; Koretsune Y; Tsutsui H; Toyoda K; Hirayama A; Yasaka M; Yamashita T; Yamaguchi T; Teramukai S; Kimura T; Kaburagi J; Takita A
    Circ Rep; 2020 Oct; 2(10):552-559. PubMed ID: 33693180
    [No Abstract]   [Full Text] [Related]  

  • 24. Comparison of Direct Oral Anticoagulant Use for the Treatment of Non-Valvular Atrial Fibrillation in Pivotal Clinical Trials vs. the Real-World Setting: A Population-Based Study from Southern Italy.
    Ingrasciotta Y; Fontana A; Mancuso A; Ientile V; Sultana J; Uomo I; Pastorello M; Calabrò P; Andò G; Trifirò G
    Pharmaceuticals (Basel); 2021 Mar; 14(4):. PubMed ID: 33805899
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prescription Patterns and Outcomes of Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulants and Warfarin: A Real-World Analysis.
    Kattoor AJ; Pothineni NV; Goel A; Syed M; Syed S; Paydak H; Mehta JL
    J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):428-434. PubMed ID: 31035795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of Direct Oral Anticoagulants in Elderly Patients With Atrial Fibrillation: A Network Meta-Analysis.
    Deng K; Cheng J; Rao S; Xu H; Li L; Gao Y
    Front Med (Lausanne); 2020; 7():107. PubMed ID: 32318577
    [No Abstract]   [Full Text] [Related]  

  • 28. Retrospective Comparison of Patients ≥ 80 Years With Atrial Fibrillation Prescribed Either an FDA-Approved Reduced or Full Dose Direct-Acting Oral Anticoagulant.
    Taoutel R; Ezekowitz MD; Chaudhry UA; Weber C; Hassan D; Gracely EJ; Kamareddine MH; Horn BI; Harper GR
    Int J Cardiol Heart Vasc; 2022 Dec; 43():101130. PubMed ID: 36246771
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Off-label dose direct oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation: A new evidence of Asian dose.
    Xu W; Lv M; Wu T; Huang N; Zhang W; Su J; Dai H; Gu P; Huang X; Du X; Li R; Zheng Q; Lin X; Liu Y; Zhang M; Liu X; Zhu Z; Zhang J
    Int J Cardiol; 2023 Jan; 371():184-190. PubMed ID: 36208678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-World Adherence and Persistence with Direct Oral Anticoagulants in Adults with Atrial Fibrillation.
    Manzoor BS; Lee TA; Sharp LK; Walton SM; Galanter WL; Nutescu EA
    Pharmacotherapy; 2017 Oct; 37(10):1221-1230. PubMed ID: 28730619
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inappropriate dosing of direct oral anticoagulants in patients with atrial fibrillation.
    Lavoie K; Turgeon MH; Brais C; Larochelle J; Blais L; Farand P; Letemplier G; Perreault S; Beauchesne MF
    J Atr Fibrillation; 2016 Dec; 9(4):1478. PubMed ID: 29250254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High Fluctuation Between Anticoagulants, Frequent Off-Label Dosing, and No Difference Concerning Outcomes: Results of a Real-Life Cohort Study.
    Eschler CM; Antelo A; Funk GC; Exadaktylos AK; Lindner G
    Am J Med; 2021 Mar; 134(3):e165-e170. PubMed ID: 33645506
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative study of hemorrhagic and ischemic complications among anticoagulants in patients undergoing cryoballoon ablation for atrial fibrillation.
    Okishige K; Nakamura T; Aoyagi H; Kawaguchi N; Yamashita M; Kurabayashi M; Suzuki H; Asano M; Shimura T; Yamauchi Y; Sasano T; Hirao K
    J Cardiol; 2017 Jan; 69(1):11-15. PubMed ID: 27160710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rates of Potentially Inappropriate Dosing of Direct-Acting Oral Anticoagulants and Associations With Geriatric Conditions Among Older Patients With Atrial Fibrillation: The SAGE-AF Study.
    Sanghai S; Wong C; Wang Z; Clive P; Tran W; Waring M; Goldberg R; Hayward R; Saczynski JS; McManus DD
    J Am Heart Assoc; 2020 Mar; 9(6):e014108. PubMed ID: 32146898
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States.
    Baker CL; Dhamane AD; Mardekian J; Dina O; Russ C; Rosenblatt L; Lingohr-Smith M; Menges B; Lin J; Nadkarni A
    Adv Ther; 2019 Jan; 36(1):162-174. PubMed ID: 30499067
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of intracardiac thrombi under phenprocoumon, direct oral anticoagulants (dabigatran and rivaroxaban), and bridging therapy in patients with atrial fibrillation and flutter.
    Zylla MM; Pohlmeier M; Hess A; Mereles D; Kieser M; Bruckner T; Scholz E; Zitron E; Schweizer PA; Katus HA; Thomas D
    Am J Cardiol; 2015 Mar; 115(5):635-40. PubMed ID: 25591898
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Contemporary Management of Direct Oral Anticoagulants During Cardioversion and Ablation for Nonvalvular Atrial Fibrillation.
    Trujillo TC; Dobesh PP; Crossley GH; Finks SW
    Pharmacotherapy; 2019 Jan; 39(1):94-108. PubMed ID: 30548542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Oral anticoagulation in atrial fibrillation: What is the guideline for using new drugs?].
    Ibáñez Pérez de Viñaspre JA; Gómez Bitrian J; Royo Hernández R; de Azúa Jiménez M; Marco López C; Urieta González L
    Semergen; 2018; 44(5):297-303. PubMed ID: 28867369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rivaroxaban or Apixaban for Non-Valvular Atrial Fibrillation - Efficacy and Safety of Off-Label Under-Dosing According to Plasma Concentration.
    Suwa M; Morii I; Kino M
    Circ J; 2019 Apr; 83(5):991-999. PubMed ID: 30918237
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A mixed methodology, non-interventional study to evaluate the use of direct oral anticoagulants in UK clinical practice for patients with a first stroke associated with non-valvular atrial fibrillation: study protocol.
    Bhat Y; Dixit A; Mistri A; Patel B; Quoraishi SH; Uprichard J
    BMC Neurol; 2019 Nov; 19(1):306. PubMed ID: 31783738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.